Clinicopathologic features of single bone metastasis in breast cancer

Basit Öğe Kaydı
dc.contributor.authorKaratas, Murat
dc.contributor.authorZengel, Baha
dc.contributor.authorDurusoy, Raika
dc.contributor.authorTasli, Funda
dc.contributor.authorAdibelli, Zehra
dc.contributor.authorSimsek, Cenk
dc.contributor.authorUslu, Adam
dc.date.accessioned2021-05-03T20:33:17Z
dc.date.available2021-05-03T20:33:17Z
dc.date.issued2021
dc.departmentEge Üniversitesien_US
dc.description.abstractThe most common site for metastasis in patients with breast cancer is the bone. in this case series, we investigated patients whose surgical and medical treatment for primary breast cancer was conducted at our center and first disease recurrence was limited to only 1 bone. We analyzed 910 breast cancer patients, 863 had no metastasis and 47 cases had a single bone metastasis >= 6 months after their first diagnosis. Demographic, epidemiological, histopathological and intrinsic tumor subtype differences between the non-metastatic group and the group with solitary bone metastases and their statistical significance were examined. Among established breast cancer risk factors, we studied twenty-nine variables. Three variables (Type of tumor surgery, TNM Stage III tumors and mixed type (invasive ductalcarsinoma + invasive lobular carcinoma) histology) were significant in multivariate logistic regression analysis. Accordingly, the risk of developing single bone metastasis was approximately 15 times higher in patients who underwent mastectomy and 4.8 and 2.8 times higher in those with TNM Stage III tumors and with mixed type (invasive ductal carcinoma + invasive lobular carcinoma) histology, respectively. in conclusion, the risk of developing single bone metastasis is likely in non-metastatic patients with Stage III tumors and possibly in mixed type tumors. Knowing this risk, especially in patients with mixed type tumors, may be instrumental in taking measures with different adjuvant therapies in future studies. Among these, treatment modalities such as prolonged hormone therapy and addition of bisphosphonates to the adjuvant treatments of stage III and mixed breast cancer patients may be considered.en_US
dc.identifier.doi10.1097/MD.0000000000024164en_US
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue1en_US
dc.identifier.pmid33429799en_US
dc.identifier.scopus2-s2.0-85099900404en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000024164
dc.identifier.urihttps://hdl.handle.net/11454/69939
dc.identifier.volume100en_US
dc.identifier.wosWOS:000612794500075en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast canceren_US
dc.subjectisolated bone metastasisen_US
dc.subjectmetastatic diseaseen_US
dc.titleClinicopathologic features of single bone metastasis in breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu